BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Vijaya Diagnostic Center Ltd.’s Q3 FY22 performance exceeded our expectation, mainly due to better-than-expected Covid-19 revenues and margins.
Revenues grew 10.9% YoY to Rs 1.1 billion (our estimate: Rs 855 million), driven mainly by a strong recovery in non-Covid volumes.
Revenue from Covid tests fell 20.4% QoQ to Rs 86 million (our estimate: Rs 28 million) with a drop in the number of cases and realization, while non-Covid revenue grew 19.5% YoY to Rs 1.0 billion (our estimate: Rs 855 million) due to a strong recovery in volumes.
Vijaya Diagnostic’s Ebitda margin shrunk 330 bps YoY to 43.2%, though it was more than our estimate of 41.8%. Adjusted profit after tax grew 2.3% to Rs 253 million, in line with the operational performance.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.